Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | EVP, CLO&Secretary | May 13, 2026 | May 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Karyopharm Therapeutics Inc.
Report date May 13, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 94,398 |
Ending reported balance
After 2026-05-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-13 · Grant · Acquired 700 · Balance 94,664 F1: Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial, as certified by the issuer's Compensation Committee on May 13, 2026. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on May 13, 2026. Row 2 · 2026-05-14 · Sale · Disposed 266 · Balance 94,398 F2: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 16, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial, as certified by the issuer's Compensation Committee on May 13, 2026. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on May 13, 2026.
F2: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 16, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2026 Filed May 15, 2026 20:02 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 266 | $9.50 | $2,527.00 |
DisclosureSEC source: 0001193125-26-226604 · ownership.xml · nonDerivative · entry 2 Mano Michael · CIK 0001837741 · EVP, CLO&Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,398 F2 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 16, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| May 13, 2026 Filed May 15, 2026 20:02 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-226604 · ownership.xml · nonDerivative · entry 1 Mano Michael · CIK 0001837741 · EVP, CLO&Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,664 F1 · shares: Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial, as certified by the issuer's Compensation Committee on May 13, 2026. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on May 13, 2026. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:28 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,526 | $9.41 | $33,177.90 |
DisclosureSEC source: 0001837741-26-000003 · ownership.xml · nonDerivative · entry 1 Mano Michael · CIK 0001837741 · EVP, CLO&Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,964 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 16, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 21:28 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 32,415 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-035661 · ownership.xml · nonDerivative · entry 1 Mano Michael · CIK 0001837741 · EVP, CLO&Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,490 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on January 31, 2027, with the remaining 50% vesting on January 31, 2028. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 20:30 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 43,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-241479 · ownership.xml · nonDerivative · entry 1 Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,075 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on December 31, 2026. Read SEC document |
| September 15, 2025 Filed Sep 16, 2025 20:34 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 234 | $6.43 | $1,504.62 |
DisclosureSEC source: 0001193125-25-205049 · ownership.xml · nonDerivative · entry 2 Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,425 F2 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 16, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| September 12, 2025 Filed Sep 16, 2025 20:34 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 612 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-205049 · ownership.xml · nonDerivative · entry 1 Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,659 F1 · shares: Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2023 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 SENTRY trial, as certified by the issuer's Compensation Committee on September 12, 2025. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on September 12, 2025. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:13 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 2,793 | $6.29 | $17,567.97 |
DisclosureSEC source: 0000950170-25-034650 · ownership.xml · nonDerivative · entry 1 Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,047 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 16, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $6.11 to $6.31, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 21:46 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $7.95 | $0.00 |
DisclosureSEC source: 0000950170-25-032280 · ownership.xml · derivative · entry 4 Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2035-02-27 F2 · derivative.exercise_price: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. F4 · derivative.exercise_date: This option was granted on February 28, 2025 pursuant to the 2022 Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter. F2 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 21:46 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 6,666 | $0.00 Strike: $7.95 | $0.00 |
DisclosureSEC source: 0000950170-25-032280 · ownership.xml · derivative · entry 3 Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,666 Underlying: Common Stock · 6,666 shares Expires 2035-02-27 F2 · derivative.exercise_price: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. F4 · derivative.exercise_date: This option was granted on February 28, 2025 pursuant to the 2022 Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter. F2 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 21:46 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032280 · ownership.xml · nonDerivative · entry 2 Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,840 F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. F3 · shares: Represents the award of RSUs pursuant to the 2022 Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in two equal annual installments beginning February 28, 2026. F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 21:46 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032280 · ownership.xml · nonDerivative · entry 1 Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,590 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended (the "2022 Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2026. F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. Read SEC document |
| September 04, 2024 Filed Sep 5, 2024 20:28 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,971 | $0.72 | $2,866.27 |
DisclosureSEC source: 0000950170-24-104038 · ownership.xml · nonDerivative · entry 1 Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 273,881 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 16, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 00:38 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon | 3,576 | $1.20 | $4,291.20 |
DisclosureSEC source: 0000950170-24-025190 · ownership.xml · nonDerivative · entry 2 Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 277,852 F3 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 16, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of performance-based restricted stock units. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| February 29, 2024 Filed Mar 5, 2024 00:38 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon | 16,973 | $1.17 | $19,858.41 |
DisclosureSEC source: 0000950170-24-025190 · ownership.xml · nonDerivative · entry 1 Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,428 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 16, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $1.12 to $1.18, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 22:35 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 147,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-023290 · ownership.xml · nonDerivative · entry 1 Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 298,401 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2025. Read SEC document |
| January 24, 2024 Filed Jan 25, 2024 23:53 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 9,167 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-007589 · ownership.xml · nonDerivative · entry 1 Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,401 F1 · shares: Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2023 that have been earned based on the level of achievement of a certain clinical milestone, as certified by the issuer's compensation committee on January 24, 2024. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs will vest on February 28, 2024, the first anniversary of the grant date, subject to continued employment through such vesting date. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 20:29 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,888 | $1.33 | $5,176.09 |
DisclosureSEC source: 0001209191-23-048161 · doc4.xml · nonDerivative · entry 1 Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,234 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 16, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 22:35 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 6,878 | $3.03 | $20,834.84 |
DisclosureSEC source: 0001209191-23-014865 · doc4.xml · nonDerivative · entry 2 Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,122 F2 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:35 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014865 · doc4.xml · nonDerivative · entry 1 Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,000 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2024. Read SEC document |
| August 31, 2022 Filed Sep 2, 2022 01:01 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $5.06 | $0.00 |
DisclosureSEC source: 0001209191-22-048396 · doc4.xml · derivative · entry 2 Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-08-30 F2 · derivative.exercise_date: This option was granted on August 31, 2022 pursuant to the Plan. The shares underlying this option vest as to 50% of the shares on August 31, 2023, with the remaining 50% vesting on August 31, 2024. Read SEC document |
| August 31, 2022 Filed Sep 2, 2022 01:01 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-048396 · doc4.xml · nonDerivative · entry 1 Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,000 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on August 31, 2023, with the remaining 50% vesting on August 31, 2024. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 20:14 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 81,000 | $0.00 Strike: $10.33 | $0.00 |
DisclosureSEC source: 0001209191-22-014621 · doc4.xml · derivative · entry 2 Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,000 Underlying: Common Stock · 81,000 shares Expires 2032-02-27 F2 · derivative.exercise_date: This option was granted on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 20:14 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 63,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014621 · doc4.xml · nonDerivative · entry 1 Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,000 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.